Search

Your search keyword '"P. G. Richardson"' showing total 6 results
Start Over Author "P. G. Richardson" Journal hemasphere
6 results on '"P. G. Richardson"'

1. P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

Author

C. Rodriguez, J. L. Kaufman, J. Laubach, D. W. Sborov, B. Reeves, A. Chari, R. Silbermann, L. J. Costa, L. D. Anderson, Jr, N. Nathwani, N. Shah, N. Bumma, A. Jakubowiak, R. Z. Orlowski, H. Pei, A. Cortoos, S. Patel, T. S. Lin, P. G. Richardson, and P. M. Voorhees

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

2. P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

Author

A. Nooka, S. Lonial, S. Grosicki, M. Hus, K. Song, T. Facon, N. S. Callander, V. Ribrag, K. Uttervall, H. Quach, V. Vorobyev, C.-K. Min, S. Cheng, L. M. Smith, J. Yu, T. Collingwood, B. Holkova, B. E. Kremer, I. V. Gupta, P. G. Richardson, and M. C. Minnema

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

4. PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

Author

P. Moreau, Marc-Steffen Raab, Kenshi Suzuki, Suresh Shelat, Mitsuo Hori, Sebastian Grosicki, Xavier Leleu, M.A. Dimopoulos, Dominik Dytfeld, Brian Rafferty, Michael Robbins, Ying-Ming Jou, Naoki Takezako, M. Popa McKiver, P. G. Richardson, J. San Miguel, and Richard Leblanc

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, Pomalidomide, medicine.disease, Internal medicine, Relapsed refractory, Medicine, Elotuzumab, business, Dexamethasone, Multiple myeloma, medicine.drug
Published
2019

5. PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Author

Larry D. Anderson, M.A. Dimopoulos, A. Bensmaine, P. Moreau, T. Vi Nguyen, Pieter Sonneveld, Matthew W Jenner, Katja Weisel, Darrell White, J. Dürig, M. Salomo, P. G. Richardson, J. San Miguel, M. Pavic, X Yu, Alessandro Corso, Teresa Peluso, M. Zaki, and Monika Engelhardt

Subjects
Oncology, medicine.medical_specialty, Bortezomib, business.industry, Line of therapy, Subgroup analysis, Hematology, medicine.disease, Pomalidomide, Internal medicine, medicine, In patient, business, Multiple myeloma, Dexamethasone, Lenalidomide, medicine.drug
Published
2019

6. S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)

Author

M.V. Mateos, A. Paner, J. Harran, A. Alegre, J. Bladé, M. Cavo, C. Maisel, A. Oriol, A. Larocca, P. G. Richardson, Jeffrey A. Zonder, X. Leleu, Noemi Puig, H. Hassoun, H. Zubair, J. Harmenberg, Amitabha Mazumder, M. Norkin, S. Thuresson, and Paula Rodriguez Otero

Subjects
Oncology, medicine.medical_specialty, Horizon (archaeology), business.industry, Daratumumab, Hematology, Pomalidomide, Dara, medicine.disease, Refractory, Internal medicine, Relapsed refractory, medicine, business, Multiple myeloma, medicine.drug
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results